Product Information
TRUVADA 200 MG-300 MG TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $59.7097 per EA under NDC 61958070101. Its NADAC has been published 658 times since Nov 28, 2013.
FDA first approved this application on Aug 2, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the emtricitabine and tenofovir disoproxil fumarate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
200; 300 mg/1; mg/1
Manufacturer
Gilead Sciences, Inc.NDC
61958070101
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATEApproval Type
New Drug (NDA)
FDA Application
NDA021752FDA Approved
8/2/2004
TE Code
AB
On Market Since
8/2/2004
Pharmacological Classes
Price Statistics
The NADAC for TRUVADA 200 MG-300 MG TABLET has been published 658 times since Nov 28, 2013, and over the history we have for it it has risen 50.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $59.7097 per EA |
|---|---|
| All-time high | $59.7933 (Apr 15, 2026) |
| All-time low | $39.5979 (Nov 28, 2013) |
| 52-week high | $59.7933 |
| 52-week low | $59.5714 |
| Median price | $59.4646 |
| Average price | $54.5025 |
| Largest weekly change | +6.9% (Feb 15, 2017) |
| Weeks tracked | 658 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the emtricitabine and tenofovir disoproxil fumarate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Gilead Sciences, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
emtricitabine and tenofovir disoproxil fumarate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRUVADA 200 MG-300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRUVADA 200 MG-300 MG TABLET, manufactured by Gilead Sciences, Inc., is $59.7097 per EA (NDC 61958070101), effective Sep 30, 2026.
How has the price of TRUVADA 200 MG-300 MG TABLET changed over time?
Over the history we have for it, the NADAC for TRUVADA 200 MG-300 MG TABLET has risen 50.8%. It has been tracked across 658 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TRUVADA 200 MG-300 MG TABLET?
Since Nov 28, 2013, the NADAC for TRUVADA 200 MG-300 MG TABLET has ranged from a low of $39.5979 (Nov 28, 2013) to a high of $59.7933 (Apr 15, 2026), with a median of $59.4646 per EA.
Are there cheaper alternatives to TRUVADA 200 MG-300 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of TRUVADA 200 MG-300 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TRUVADA 200 MG-300 MG TABLET?
TRUVADA 200 MG-300 MG TABLET (NDC 61958070101) is labeled by Gilead Sciences, Inc., and CMS classifies it as a brand product.